The retrospective analysis results of the endometrial tissue pathological conditions development




endometrial hyperplasia, atypical endometrial hyperplasia, malignancy


Hyperplastic processes of endometrium are one of the most common pathologies of the uterus mucosa, an interest in its study is due to an increase in the frequency of occurrence, the ability to both self-healing and malignancy.

Purpose of the study: to investigate the detection rate of endometrial proliferative changes  depending on the age of woman.

Materials and methods. A retrospective medical documentation analysis of the Department of Pathology was conducted. 2196 pathologic findings of endometrial tissue samples were investigated. 1404 specimen were hyperplastic states, 688 were endometrial polyps, and 104 others were endometrial states after total or subtotal uterine removal after surgery. Histological conditions were distributed according to patients’ age categories. Results of the study were processed statistically using variation statistics with Student's criterion, using standard computer systems.

Results. The analysis shows an increase in frequency of endometrial proliferative changes in perimenopausal patients on the background of endometrial pathological changes detection in all age categories. Atypical forms of simple and complex hyperplasia of the endometrium can be traced in all age categories, with a maximum frequency of manifestation in similar age-related periods – 41–45 years and 46–50 years. Morphological signs of endometrial tissue malignancy were first established in the age group of 46–50 years, which coincides with the age of the onset of menopause in the Odesa region, with subsequent relative increase in the frequency and aggressiveness of the process with age. These age groups focus doctors to be more careful about pathological manifestations.

Conclusion. As a result of retrospective analysis of histopathological examinations it was found that the main factor in detecting pathological conditions of the endometrium is a woman's age of perimenopausal period, which can be considered as an early marker of diagnosis, leading to treatment prospects and general therapeutic tactics, for the future diagnostics and detection of others immunohistochemical and molecular genetic markers in women with hyperplastic processes in endometrial tissue.

Author Biographies

V. V. Artyomenko, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department No. 2

Z. V. Chumak, Odesa National Medical University, City Center for Climacteric Problems, Odesa

PhD, assistant, Obstetrics and Gynecology Department No. 2

M. V. Shapoval, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department No. 2


  1. Vovk, I.B., Gorban, N.E., Borysiuk, O.Y. “Endometrial hyperplasia (Clinical lecture).” Woman’s Health 5.111 (2016): 10–8.
  2. World Health Organization. Cancer. Fact sheet. Genewa. WHO (2017).
  3. Tatarchuk, T.F., Kalugina, L.B., Tutchenko, T.N. “Hyperplastic processes of endometrium: what’s new?” Reproductive Endocrinology 5.25 (2015): 7–13.
  4. Doddamani, U.G., Doddamani, G.B., Katageri, G. “Clinicopathological Correlation of Endometrium in Abnormal Uterine Bleeding.” Sch J App Med Sci 2.1A (2014): 46–9.
  5. Grygorenko, A.N., Gordiychuk, A.B. “Endometrial hyperplasia: There are more questions than answer.” Reproductive Endocrinology 3.35 (2017): 31–43.
  6. Orazov, M.R. “Debating points of endometrium hyperplasia case management.” Obstetrics and Gynecology. News, opinions, training 3 (2016): 46–58. Оразов, М.Р.
  7. Makhina, E.V., Pichigina, A.K., Koldysheva, E.V., et al. “Diagnostic and prognostic value of endometrial cell proliferative activity in hyperplastic and neoplastic processes.” Fundamental Researches 10 (2014): 420–7.
  8. Demakova, N.A., Altukhova, O.B., Pakhomov, S.P., et al. “Molecular genetic mechanisms of the endometrial hyperplastic processes.” Scientific reports 4.175 Issue 25 (2014): 177–82.
  9. Davydov, M.I., Gantsev, S.K. Oncology: textbook. Moscow. GEOTAR-Media (2019): 920 p.
  10. Bednarek, M., Constantinou, M., et al. “Evolution of genomic imbalance in endometrial hyperplasia and carcinoma.” Gynecol Pol 85.11 (2014): 828–32.
  11. Chumak, Z.V., Zelinsky, O.O., Shapoval, M.V. “Immune Histochemical and Molecular-genetic Markers of Hyperplastic and Neoplastic Endometrium.” Reports of Morphology 2 (2015): 547–51.
  12. Chernukha, G.E., Asaturova, A.V., Ivanov, I.A., et al. “Endometrial lesion’s pattern in different age groups.” Obstetrics and Gynecology 4 (2009): 11–5.
  13. Lehner, R., et al. “Quantitative Analysis of Telomerase hTERT mRNA and Telomerase Activity in Endometrioid Adenocarcinoma and in Normal Endometrium.” Gynecologic Oncology 84 (2002): 120–5.
  14. Litta, P., Bartolucci, C., Saccardi, C., et al.“Atypical endometrial lesions: hysteroscopic resection as an alternative to hysterectomy.” Eur J Gynaecol Oncol 34.1 (2013): 51–3.
  15. Clark, T.J., Mann, C.H., Shah, N., et al. “Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia.” Acta Obstet Gynecol Scand 80 (2001): 784–93.
  16. Gallos, I.D., Krishan, P., Shehmar, M., et al. “Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.” Hum Reprod 28 (2013): 1231–6.
  17. Amalinei, C., Cianga, C., Balan, R., et al. “Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosid related molecules, and gelatinases in non-neoplastic and neoplastic endometrium.” Ann Anat 193.1 (2011): 43–5.
  18. Jarboe, E.A., Mutter, G.L. “Endometrial intraepithelial neoplasia.” Semin Diagn Pathol 27.4 (2010): 215–25.
  19. Jianying, X.U., et al. “Expression of Survivin Gene among Human Normal Endometrium, Atypical Hyperplasia of Endometrium and Endometrial Carcinoma.” Journal of Reproduction and Contraception 21.3 (2010): 129–35.
  20. Reed, S.D., Newton, K.M., Garcia, R.L., et al. “Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.” Obstet Gynecol 116 (2010): 365–73.
  21. Monaghan, P. “Organismal stress, telomeres and life histories.” The Journal of Experimental Biology 217 (2014): 57–66.
  22. Ozdegirmenci, O., Kayikcioglu, F., Bozkurt, U., et al. “Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.” Gynecol Obstet Invest 72 (2011): 10–4.
  23. Park, J.Y., Lee, S.H., Seong, S.J., et al. “Progestin retreatment in patients with recurrent endometrial adenocarcinoma after successful fertility sparing management using progestin.” Gynecol Oncol 129 (2013): 7–11.
  24. Kotdawala, P., Kotdawala, S., Nagar, N. “Evaluation of endometrium in perimenopausal abnormal uterine bleeding.” J Midlife Health 4.1 (2013): 16–21.
  25. Orbo, A., Arnes's, M., Myreng, L., et al. “HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.” British Journal of Cancer 115.9 (2016). DOI: 10.1038/bjc.2016.330




How to Cite

Artyomenko, V. V., Chumak, Z. V., & Shapoval, M. V. (2020). The retrospective analysis results of the endometrial tissue pathological conditions development. REPRODUCTIVE ENDOCRINOLOGY, (55), 48–52.